Evicenter
Ibrance (palbociclib) in HR-positive HER2-negative advanced or metastatic breast cancer
Manufacturer
Pfizer Laboratories Div Pfizer Inc
Questions
28
Last updated

All questions

Dosing and administration: Ibrance (palbociclib) in HR-positive HER2-negative advanced or metastatic breast cancer

2 questions · 4 sources

Dosing

What is the recommended Ibrance dose and schedule?

Note: The first passage is from the IBRANCE tablets Prescribing Information, the second from the IBRANCE capsules Prescribing Information, the third from the tablets and capsules page, and the fourth from the dosing page of the Ibrance HCP site, under HR+/HER2- mBC.

Treatment combinations

Do premenopausal women taking Ibrance need an LHRH agonist?